Facial angiofibromas are dermatological manifestations of tuberous sclerosis complex, a neurocutaneous disorder characterized by excess cell growth and proliferation. Oral rapamycin has been used to treat visceral tuberous sclerosis–related tumors; however, the side effect profile of this medicine precludes its routine use in patients lacking significant internal involvement. The authors formulated a novel rapamycin cream that is easy to compound and apply, does not cause local or systemic side effects, and results in a dramatic improvement of facial angiofibromas.
CrinoPBNathansonKLHenskeEP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–1356.
2.
BoixedaPSanchez-MirallesEAzanaJM. CO2, argon, and pulsed dye laser treatment of angiofibromas. J Dermatol Surg Oncol. 1994;20:808–812.
3.
GomesAAGomesYVLimaFB. Multiple facial angiofibromas treated with high-frequency equipment. An Bras Dermatol. 2011;86:S186–S189.
4.
HoriKSoejimaKNozakiM. Treatment of facial angiofibroma of tuberous sclerosis using cultured epithelial autografts. Ann Plast Surg. 2006;57:415–417.
5.
TurkmenMErtamIUnalI. Facial angiofibromas of tuberous sclerosis: successful treatment with podophyllin. J Eur Acad Dermatol Venereol. 2009;23:713–714.
6.
WeissETGeronemusRG. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med. 2010;42:357–360.
7.
HofbauerGFMarcollo-PiniACorsencaA. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159:473–475.
8.
Kaufman McNamaraECurtisARFleischerABJr. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat. 2012;23:46–48.
9.
MicozkadiogluHKocZOzelsancakR. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail. 2010;32:1233–1236.
10.
DeKlotzCMOgramAESinghS. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol. 2011;147:1116–1117.
11.
FosterRSBintLJHalbertAR. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53:52–56.
12.
HaemelAKO’BrianALTengJM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715–718.
13.
KoenigMKHebertAARobersonJ. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12:121–126.
14.
MutizwaMMBerkDRAnadkatMJ. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1)) in two patients with tuberous sclerosis. Br J Dermatol. 2011;165:922–923.
15.
TruchueloTDiaz-LeyBRiosL. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol Online J. 2012;18:15.
16.
Wataya-KanedaMTanakaMNakamuraA. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165:912–916.
